# A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

> **NCT05238454** · PHASE2 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** SCTV01C
- **BIOLOGICAL:** Sinopharm inactivated COVID-19 vaccine
- **BIOLOGICAL:** Comirnaty

## Key facts

- **NCT ID:** NCT05238454
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-20
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238454, "A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05238454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*